- Home
- DPRO vs IMNN Comparison
DPRO vs IMNN Comparison
Compare DPRO & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DPRO
- IMNN
- Stock Information
- Founded
- DPRO 1998
- IMNN 1982
- Country
- DPRO Canada
- IMNN United States
- Employees
- DPRO N/A
- IMNN N/A
- Industry
- DPRO Aerospace
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- DPRO Industrials
- IMNN Health Care
- Exchange
- DPRO Nasdaq
- IMNN Nasdaq
- Market Cap
- DPRO 10.4M
- IMNN 12.1M
- IPO Year
- DPRO N/A
- IMNN 1985
- Fundamental
- Price
- DPRO $2.68
- IMNN $0.96
- Analyst Decision
- DPRO Strong Buy
- IMNN Buy
- Analyst Count
- DPRO 2
- IMNN 2
- Target Price
- DPRO $5.25
- IMNN $14.00
- AVG Volume (30 Days)
- DPRO 2.1M
- IMNN 32.7M
- Earning Date
- DPRO 08-12-2025
- IMNN 08-13-2025
- Dividend Yield
- DPRO N/A
- IMNN N/A
- EPS Growth
- DPRO N/A
- IMNN N/A
- EPS
- DPRO N/A
- IMNN N/A
- Revenue
- DPRO $4,716,450.00
- IMNN N/A
- Revenue This Year
- DPRO $94.01
- IMNN N/A
- Revenue Next Year
- DPRO $95.14
- IMNN N/A
- P/E Ratio
- DPRO N/A
- IMNN N/A
- Revenue Growth
- DPRO 7.90
- IMNN N/A
- 52 Week Low
- DPRO $1.55
- IMNN $0.37
- 52 Week High
- DPRO $6.09
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- DPRO 58.12
- IMNN 43.51
- Support Level
- DPRO $2.08
- IMNN $0.93
- Resistance Level
- DPRO $3.22
- IMNN $1.03
- Average True Range (ATR)
- DPRO 0.39
- IMNN 0.26
- MACD
- DPRO 0.03
- IMNN -0.10
- Stochastic Oscillator
- DPRO 41.83
- IMNN 2.71
About DPRO Draganfly Inc.
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).